# Hedyotis corymbosa (Hedyotis corymbosa (L.) Lam.)

**Canonical URL:** https://ingredients.hermeticasuperfoods.com/ingredients/hedyotis-corymbosa-hedyotis-corymbosa-l-lam
**Data Source:** Hermetica Superfoods Ingredient Encyclopedia
**Updated:** 2026-04-04
**Evidence Score:** 1 / 10
**Category:** Southeast Asian
**Also Known As:** Hedyotis corymbosa (L.) Lam., Oldenlandia corymbosa L., rumput mutiara, flat-top mille graines, corymbose hedyotis

## Overview

Hedyotis corymbosa contains ursolic acid, anthraquinones (including 2-hydroxy-1-methoxyanthraquinone), ferulic acid, and β-sitosterol that exert [antimicrobial](/ingredients/condition/immune-support) activity through membrane disruption and enzyme inhibition, with ethyl acetate fractions demonstrating minimum inhibitory concentrations (MIC) averaging 100 µg/mL against Staphylococcus aureus, Salmonella enterica, Escherichia coli, and Bacillus subtilis. Preclinical in vitro evidence from closely related Hedyotis diffusa extrapolates anticancer potential through p53 upregulation, Bax/Bcl-2 modulation, and caspase-8 activation in hepatocellular and leukemia cell lines, though no human clinical trials have been conducted for either species.

## Health Benefits

- **[Antimicrobial](/ingredients/condition/immune-support) Activity**: Ethyl acetate fractions of the whole-plant methanol extract inhibit gram-positive and gram-negative bacteria including S. aureus, E. coli, S. enterica, and B. subtilis at MIC values averaging 100 µg/mL, driven primarily by ursolic acid and ferulic acid acting on bacterial membranes and metabolic enzymes.
- **Antifungal Properties**: Crude extracts demonstrate antifungal zones of inhibition measuring 12.5–14.3 mm at 100 µg/mL against Candida species in agar well diffusion assays, suggesting potential application in superficial fungal infections common in tropical populations.
- **Anticancer Potential (Preclinical)**: Extrapolated from the closely related H. diffusa, anthraquinone compounds such as 2-hydroxymethyl-1-hydroxy anthraquinone exhibit IC50 values of approximately 45 µM against Caco-2 colorectal cancer cells, with mechanisms involving p53 upregulation and apoptosis induction.
- **[Anti-inflammatory](/ingredients/condition/inflammation) Potential**: Ferulic acid and scopoletin, both isolated from H. corymbosa, are established inhibitors of cyclooxygenase enzymes and NF-κB signaling in preclinical models of other plant species, suggesting plausible but unconfirmed anti-inflammatory activity for this herb.
- **[Hepatoprotective](/ingredients/condition/detox) Activity**: Ursolic acid, a triterpene isolated from H. corymbosa methanol extracts, is documented in other botanical contexts to modulate Bax/p53/Bcl-2 ratios in HepG2 hepatocellular carcinoma cells, providing a mechanistic basis for traditional use in liver-related conditions.
- **[Antioxidant](/ingredients/condition/antioxidant) Properties**: Phenolic compounds including ferulic acid and scopoletin contribute free-radical scavenging capacity, as ferulic acid is a well-characterized antioxidant with documented DPPH radical scavenging activity in related Rubiaceae species, though H. corymbosa-specific ORAC or DPPH values are not yet published.
- **Traditional Antimalarial and Antipyretic Use**: Ethnobotanical records from Southeast Asia document H. corymbosa whole-plant decoctions used for fever management and as a supportive treatment in malaria-endemic regions, aligning with the antimicrobial and anti-inflammatory profile of its phytochemical constituents.

## Mechanism of Action

Ursolic acid and ferulic acid, isolated from the ethyl acetate fraction of H. corymbosa whole-plant methanol extracts, exert antibacterial effects primarily through disruption of bacterial cell membrane integrity and inhibition of key metabolic enzymes, contributing to the observed MIC of approximately 100 µg/mL against multiple gram-positive and gram-negative pathogens. Anthraquinone derivatives including 2-hydroxy-1-methoxyanthraquinone and 3-hydroxy-1,2-dimethoxyanthraquinone intercalate into DNA or inhibit topoisomerase function, mechanisms well established for anthraquinone-class compounds in closely related Hedyotis species. Scopoletin, a coumarin-class compound, inhibits monoamine oxidase activity and suppresses prostaglandin synthesis, potentially contributing to the herb's traditional antipyretic and [anti-inflammatory](/ingredients/condition/inflammation) applications. In extrapolated data from H. diffusa, related phytochemicals activate the p38 MAPK pathway while downregulating ERK1/2 phosphorylation, induce caspase-8-mediated extrinsic apoptosis, and shift the Bax/Bcl-2 ratio toward pro-apoptotic signaling in cancer cell lines, pathways plausibly operative in H. corymbosa given shared phytochemical composition.

## Clinical Summary

No clinical trials have been conducted specifically for Hedyotis corymbosa in any indication, including the [antimicrobial](/ingredients/condition/immune-support), anticancer, or [anti-inflammatory](/ingredients/condition/inflammation) contexts suggested by preclinical data. All quantified outcomes—MIC values of 100 µg/mL for antibacterial activity and antifungal inhibition zones of 12.5–14.3 mm—derive from in vitro cell-free or cell-based assays that cannot be directly translated to human therapeutic doses or clinical efficacy. Anticancer cell line studies using IC50 endpoints (e.g., 45 µM for anthraquinone compounds against Caco-2 cells) are drawn from H. diffusa research and lack validation in H. corymbosa extracts or animal tumor models. Confidence in clinical benefit remains very low; the herb is best classified as a traditional remedy with preliminary phytochemical characterization and speculative therapeutic potential pending rigorous preclinical and clinical investigation.

## Nutritional Profile

Hedyotis corymbosa is not consumed as a significant dietary nutritional source and lacks published proximate composition analyses for macronutrients or essential micronutrients. Its primary value lies in secondary metabolite phytochemicals: ursolic acid (triterpenoid), 3β-hydroxyolean-11-en-28,13β-olide (triterpenoid), β-sitosterol (phytosterol), stigmastane-3,6-dione (steroidal diketone), ferulic acid (hydroxycinnamic acid phenolic), scopoletin (coumarin), 2-hydroxy-1-methoxyanthraquinone, and 3-hydroxy-1,2-dimethoxyanthraquinone—the latter six contributing [antioxidant](/ingredients/condition/antioxidant) and [antimicrobial](/ingredients/condition/immune-support) bioactivity. Specific concentrations of these compounds in plant material are unpublished for H. corymbosa, though ferulic acid in the closely related H. diffusa ranges from 0 to 7.885 mg/g dry weight depending on geographic origin and extraction method. Polysaccharide content analogous to H. diffusa (reported at ~15.10% dry weight in that species) is plausible but unquantified for H. corymbosa; bioavailability of phenolic and triterpenoid constituents is expected to be low without lipid-based or nanoemulsion delivery systems, consistent with the pharmacokinetic challenges shared across this compound class.

## Dosage & Preparation

- **Traditional Whole-Plant Decoction**: Dried whole herb (5–15 g) simmered in water for 20–30 minutes; consumed as tea 2–3 times daily in Southeast Asian folk medicine traditions, though no validated therapeutic dose exists.
- **Methanol Extract (Research Grade)**: Whole plant extracted with 95% methanol followed by liquid-liquid partitioning into ethyl acetate, n-butanol, and aqueous fractions; ethyl acetate fraction is most bioactive and used at 100 µg/mL in in vitro assays.
- **Ethyl Acetate Fraction**: Most [antimicrobial](/ingredients/condition/immune-support)ly active fraction in published studies; tested at 100 µg/mL in agar well diffusion and MIC assays against bacterial and Candida species; no human dose equivalent established.
- **Standardization**: No commercial standardization protocols published; no standardized extract products with defined ursolic acid or ferulic acid percentages are documented for this species specifically.
- **Timing and Administration**: Traditional use favors oral decoctions taken with meals; no pharmacokinetic data exists to inform optimal timing, bioavailability enhancement strategies, or food-interaction considerations.
- **Note on Dose Translation**: In vitro effective concentrations (100 µg/mL) cannot be directly converted to human oral doses without bioavailability and pharmacokinetic studies, which are currently absent for this species.

## Safety & Drug Interactions

No formal human safety studies, toxicology assessments, or pharmacovigilance data have been published for Hedyotis corymbosa, and its safety profile in humans remains entirely uncharacterized beyond the absence of reported acute toxicity in traditional use settings. In vitro [antimicrobial](/ingredients/condition/immune-support) assays at 100 µg/mL concentrations have not flagged cytotoxic effects on mammalian cells in available publications, suggesting low acute toxicity at tested concentrations, but this cannot substitute for validated LD50 studies, genotoxicity panels, or repeat-dose toxicity evaluations. No drug interaction data exists; however, ferulic acid in other contexts has demonstrated mild antiplatelet activity, suggesting theoretical caution when combined with anticoagulants such as warfarin or antiplatelet agents like clopidogrel, though this has not been investigated for H. corymbosa specifically. Pregnancy and lactation safety is entirely unknown; traditional herbal use in these populations has not been systematically documented or evaluated, and avoidance during pregnancy and breastfeeding is prudent given the absence of safety data.

## Scientific Research

The evidence base for H. corymbosa consists exclusively of in vitro preclinical studies, with no published randomized controlled trials, cohort studies, or human pharmacokinetic data identified in available literature. Available studies are limited to agar well diffusion assays and MIC determinations documenting antibacterial and antifungal activity of crude extracts and isolated compounds against a panel of reference bacterial strains, with no animal toxicology models or dose-escalation studies reported. Anticancer mechanistic data frequently cited in traditional use contexts derives from H. diffusa research rather than H. corymbosa itself, representing a significant species-level evidential gap that limits direct extrapolation. The phytochemical isolation work identifying the eight major compounds (ursolic acid, ferulic acid, β-sitosterol, scopoletin, stigmastane-3,6-dione, 3β-hydroxyolean-11-en-28,13β-olide, and two anthraquinones) provides a credible chemical foundation for observed bioactivities but does not constitute clinical efficacy evidence.

## Historical & Cultural Context

Hedyotis corymbosa has been used for centuries in the traditional medicine systems of Southeast Asia and South Asia, including Ayurveda-adjacent folk traditions in India and herbalism in Thailand, Malaysia, and Indonesia, primarily as a remedy for infections, fever, and [inflammatory](/ingredients/condition/inflammation) conditions. In Thai traditional medicine, the herb is referenced among plants with anticancer applications, often conflated with the closely related Hedyotis diffusa (Bai Hua She She Cao) used extensively in Traditional Chinese Medicine for hepatocellular carcinoma and leukemia management. Regional preparations across the Malay Archipelago involve crushing the fresh whole plant into poultices applied to skin infections or preparing aqueous decoctions for systemic fever and urinary tract complaints. The plant's common name rumput mutiara, meaning 'pearl grass' in Malay, references the characteristic small white flowers resembling pearls along its stems, reflecting the deep cultural familiarity with this species across tropical agricultural communities.

## Synergistic Combinations

In traditional Southeast Asian practice, H. corymbosa is often combined with other Rubiaceae or [antimicrobial](/ingredients/condition/immune-support) herbs such as Morinda citrifolia (noni) or Andrographis paniculata, where ferulic acid from H. corymbosa may complement the andrographolide-driven NF-κB inhibition of Andrographis, creating additive [anti-inflammatory](/ingredients/condition/inflammation) and antimicrobial effects through complementary mechanistic pathways. Ursolic acid from H. corymbosa has demonstrated synergy with conventional chemotherapeutic agents in H. diffusa literature by sensitizing cancer cells through Bcl-2 downregulation, suggesting potential combinatorial value with apoptosis-targeting oncology drugs, though this has not been tested with H. corymbosa extracts directly. The anthraquinone fraction may exhibit additive antimicrobial effects when combined with β-sitosterol-rich plant oils such as sea buckthorn or black seed oil, as membrane-disrupting and enzyme-inhibiting mechanisms may converge on bacterial targets through independent chemical scaffolds.

## Frequently Asked Questions

### What is Hedyotis corymbosa used for traditionally?

Hedyotis corymbosa is used in Southeast Asian and South Asian folk medicine primarily as an antimicrobial remedy for bacterial and fungal infections, fever management, and in Thai traditional medicine as a supportive plant in cancer-related protocols. Whole-plant decoctions prepared by boiling 5–15 g of dried herb are the most common traditional preparation, consumed orally to address urinary tract infections, skin conditions, and inflammatory ailments. Its use is sometimes conflated with the closely related Hedyotis diffusa, which carries a more extensive anticancer tradition in Chinese herbal medicine.

### What bioactive compounds are found in Hedyotis corymbosa?

Eight major compounds are isolated from H. corymbosa methanol extracts: ursolic acid, β-sitosterol, ferulic acid, scopoletin, stigmastane-3,6-dione, 3β-hydroxyolean-11-en-28,13β-olide, and two anthraquinones (2-hydroxy-1-methoxyanthraquinone and 3-hydroxy-1,2-dimethoxyanthraquinone). These phytochemicals span triterpenoid, steroidal, phenolic acid, coumarin, and anthraquinone chemical classes, each contributing distinct biological activities including membrane disruption, free-radical scavenging, and potential DNA intercalation. Published concentrations within the plant material are not yet available for this species specifically.

### Is Hedyotis corymbosa the same as Hedyotis diffusa?

Hedyotis corymbosa and Hedyotis diffusa are distinct but closely related species within the Rubiaceae family, sharing overlapping phytochemical profiles including ursolic acid and anthraquinone compounds but differing in morphology, geographic distribution emphasis, and depth of scientific study. H. diffusa (Bai Hua She She Cao) has a substantially larger body of preclinical anticancer research, particularly in Chinese medicine contexts targeting liver, colon, and leukemia cell lines, while H. corymbosa research has focused predominantly on antimicrobial activity. Conflation of the two species in traditional practice and some literature is common but scientifically problematic, as compound concentrations and pharmacological profiles may differ meaningfully between them.

### Are there any clinical trials on Hedyotis corymbosa?

No clinical trials have been conducted on Hedyotis corymbosa in any therapeutic indication as of the available published literature. All efficacy data derives from in vitro cell-free antimicrobial assays (MIC and agar well diffusion) and limited extrapolation from Hedyotis diffusa cell line studies, neither of which constitutes clinical evidence of human benefit. Anyone considering its therapeutic use should be aware that efficacy and safety in humans remain unestablished, and consultation with a qualified healthcare provider is essential.

### Is Hedyotis corymbosa safe to use, and are there drug interactions?

Hedyotis corymbosa lacks formal human safety data, and no toxicology studies, maximum tolerated dose assessments, or pharmacovigilance reports have been published for this species. In vitro studies have not flagged mammalian cytotoxicity at the concentrations tested (100 µg/mL), and traditional use in tropical Asia has not generated documented reports of serious adverse events, but this is insufficient evidence to confirm human safety. Theoretical caution is warranted when combining it with anticoagulant medications such as warfarin, given ferulic acid's known antiplatelet properties in other research contexts, and use during pregnancy or breastfeeding is not recommended due to complete absence of safety data in these populations.

### How does Hedyotis corymbosa combat bacterial infections at the molecular level?

Hedyotis corymbosa's antimicrobial activity is primarily driven by ursolic acid and ferulic acid, which work by disrupting bacterial cell membranes and inhibiting key metabolic enzymes. Studies show that ethyl acetate extracts of the plant effectively inhibit both gram-positive bacteria (like S. aureus and B. subtilis) and gram-negative bacteria (like E. coli and S. enterica) at average minimum inhibitory concentrations (MIC) of 100 µg/mL. This dual action on membrane integrity and enzymatic function makes it effective against a broad spectrum of pathogenic bacteria.

### What form of Hedyotis corymbosa extract is most effective for antimicrobial benefits?

Ethyl acetate fractions of whole-plant methanol extracts demonstrate superior antimicrobial potency compared to crude preparations, with MIC values averaging 100 µg/mL against common pathogens. The fractionation process concentrates the active compounds ursolic acid and ferulic acid, which are responsible for the membrane-disrupting and enzyme-inhibiting effects. For maximum antimicrobial efficacy, standardized extracts targeting these specific bioactive components are preferred over whole-plant crude extracts.

### Is Hedyotis corymbosa effective against fungal infections, and what does research show?

Crude extracts of Hedyotis corymbosa demonstrate antifungal properties, though research on fungal efficacy is less extensively documented compared to its well-characterized antimicrobial activity against bacteria. The plant's bioactive compounds likely contribute to antifungal action through similar mechanisms of cellular disruption, but clinical evidence and specific MIC values for fungal pathogens require further investigation. More targeted research comparing antifungal potency across different extract types and fungal species would help clarify its effectiveness for fungal applications.

---

*Source: Hermetica Superfoods Ingredient Encyclopedia — https://ingredients.hermeticasuperfoods.com*
*License: CC BY-NC-SA 4.0 — Attribution required. Commercial use: admin@hermeticasuperfoods.com*